MyBCTeam

Are you switching from Herceptin to Kadcyla along with radiation therapy?

Yes, this is a common treatment approach for HER2-positive breast cancer. Kadcyla (ado-trastuzumab emtansine or T-DM1) is often recommended when there are still signs of cancer after initial treatment with chemotherapy and HER2-targeted therapy like Show Full Answer

Are you switching from Herceptin to Kadcyla along with radiation therapy?

Yes, this is a common treatment approach for HER2-positive breast cancer. Kadcyla (ado-trastuzumab emtansine or T-DM1) is often recommended when there are still signs of cancer after initial treatment with chemotherapy and HER2-targeted therapy like Herceptin.

Kadcyla combines trastuzumab (the active ingredient in Herceptin) with a chemotherapy drug called emtansine. This combination delivers chemotherapy directly to breast cancer cells, which can help reduce damage to healthy tissue.

Studies show that Kadcyla can improve outcomes significantly. After about 7 years, 89.1% of people who received Kadcyla were alive, compared to 84.4% of those treated with Herceptin alone. It also reduced the risk of cancer returning.

Radiation therapy can be given at the same time as targeted therapies like Kadcyla. Research shows that combining surgery, targeted therapy, and radiation can be an effective treatment strategy for HER2-positive breast cancer.

Keep in mind that Kadcyla may cause more side effects than Herceptin alone. Your oncologist should explain potential side effects before you start treatment. Don't hesitate to ask questions about why this change is being recommended for your specific situation.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

When Is HER2-Positive Breast Cancer Most Likely To Recur?

6 Facts About HER2 Protein, Targeted Therapy, and Other Treatments